The social and economic burden of frontotemporal degeneration
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 1, 2017
- Accepted in final form August 25, 2017
- First Published October 4, 2017.
Article Versions
- Previous version (October 4, 2017 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- James E. Galvin, MD, MPH,
- David H. Howard, PhD,
- Sharon S. Denny, MA,
- Susan Dickinson, MSGC and
- Nadine Tatton, PhD
- James E. Galvin, MD, MPH,
Phase 2 double-blind, placebo-controlled trial of Nilotinib in patients with mild to moderate AD. PI: R. Scott Turner, MD (Sponsor: Alzheimer Drug Discovery Foundation) 2016-present; Role: Chair, DSMB Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer Disease. PI: Ana Pereira, MD (Sponsor: Alzheimer Drug Discovery Foundation) 2012-present; Role: Chair, DSMB A Preliminary Study of Carvedilol for the treatment of Alzheimer?s Disease (R01 AG00035546) PI: Paul Rosenberg, MD. (Sponsor: National Institute on Aging) 2011-present, Role: Member, DSMB
NONE
NONE
Alzheimer disease and associated disorders, editorial board, 2005- present Neurodegenerative disease management, editorial board, 2012-present
NONE
NONE
NONE
Axovant Biogen Lilly Eisai
NONE
NONE
NONE
Axovant - clinical trial Biogen - clinical trial
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David H. Howard, PhD,
NONE
NONE
NONE
International Journal of Health Economics and Management, Editor-in-Chief, 2017
NONE
NONE
NONE
Association for Frontotemporal Degeneration The Center for Discovery
NONE
NONE
NONE
NONE
National Institutes of Health, PI, R01CA208758-01A1, 2017- Agency for Healthcare Research and Quality, PI, R03HS24613-01, 2016
NONE
Robert Wood Johnson Foundation, 73800
NONE
NONE
NONE
NONE
NONE
NONE
- Sharon S. Denny, MA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Susan Dickinson, MSGC and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nadine Tatton, PhD
NONE
NONE
NONE
NONE
(1) US 7,160,857 Tatton et al. Methods for increasing Schwann cell survival are disclosed. The methods of the invention are useful for the treatment of conditions such as peripheral neuropathies, including diabetic neuropathies.The present invention provides methods for increasing Schwann cell survival in a patient or in vitro, or for treating a peripheral neuropathy in a subject suffering from, or susceptable to, a peripheral neuropathy. (2) US 6,492,427 Shankar et al. Methods for treating multiple sclerosis. Methods for increasing oligodendrocyte survival are disclosed. The methods of the invention are useful for the treatment of Multiple Sclerosis. It has now been discovered that certain compounds are capable of increasing survival of oligodendrocytes. The invention provides methods for increasing survival of oligodendrocytes both in vivo and in vitro, of preventing or inhibiting death of oligodendrocytes, of preventing or inhibiting the progression of Multiple Sclerosis, and methods for treating Multiple Sclerosis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute for Healthy Aging and Lifespan Studies (J.E.G.), Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton; Emory University (D.H.H.), Atlanta, GA; and Association for Frontotemporal Degeneration (S.S.D., S.D., N.T.), Radnor, PA.
- Correspondence to Dr. Galvin: galvinj{at}health.fau.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- RE: test KP UPDATE
- kathy pieper, editor, Neurology Journal
Submitted November 13, 2017
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.